CureVac (CVAC) Company Report

Analyst Coverage

Research analysts who have asked questions during CureVac earnings calls.

Mani Foroohar

Leerink Partners

6 questions for CVAC

Also covers: ADVM, ALNY, ARWR +9 more

Roy Buchanan

Citizens JMP

5 questions for CVAC

Also covers: ABUS, CDTX, DVAX +5 more

Chen Yang

Bank of America

4 questions for CVAC

Also covers: AMLX, NMRA

Ellie Merle

UBS Group AG

4 questions for CVAC

Also covers: ALNY, ALT, ARVN +12 more

Jonathan Miller

Evercore ISI

3 questions for CVAC

Also covers: APLS, ARVN, ATRA +8 more

Jiale Song

Jefferies Financial Group Inc.

2 questions for CVAC

Also covers: ACRS, CRVS, CTMX +12 more

Max Star

Goldman Sachs

2 questions for CVAC

Umer Raffat

Evercore ISI

2 questions for CVAC

Also covers: ALKS, AMGN, BHC +15 more

Eliana Merle

UBS

1 question for CVAC

Also covers: ALNY, APLS, ARVN +17 more

Rajan Sharma

Goldman Sachs Group, Inc.

1 question for CVAC

Also covers: ARGX, AUTL, AZN +6 more

Roger Song

Jefferies

1 question for CVAC

Also covers: AADI, AKBA, ALT +13 more

Latest news

Recent press releases and 8-K filings for CVAC.

CureVac Shareholders Approve BioNTech Exchange Offer Proposals

CVAC

M&A

Proxy Vote Outcomes

Takeover Bid

CureVac N.V. shareholders approved all proposals related to BioNTech SE's public exchange offer for all outstanding shares at an Extraordinary General Meeting held on November 25, 2025.
The proposals were approved with an overall approval rate of over 99.16% of the votes cast.
Key approvals included the conditional legal merger of CureVac with CureVac Merger B.V. and the subsequent sale of CureVac SE shares to BioNTech SE, both receiving over 99.94% of the valid votes cast.
The exchange offer is set to expire at 9:00 am Eastern Time on December 3, 2025, with a recommended tender deadline of 6:00 pm Eastern Time on December 2, 2025.

Nov 26, 2025, 3:10 PM

6-K

CureVac Reports Q3 2025 Revenue Decline Amid BioNTech Takeover Progress

CVAC

Earnings

M&A

Guidance Update

CureVac reported Q3 2025 revenue of €54.13 million, a decline from the previous year, yet exceeded analyst forecasts, with GAAP EPS at €1.21.
The company maintains a strong cash position of €416.1 million, projecting a cash runway through 2028, supported by strategic restructuring and cost-saving measures.
The planned acquisition by BioNTech is progressing, having received German Federal Cartel Office clearance, with the public exchange offer period open until December 3, 2025.
CureVac exhibits a strong balance sheet, highlighted by a current ratio of 6.17, a debt-to-equity ratio of 0.06, and an interest coverage ratio of 467.1.

Nov 24, 2025, 12:23 PM

Morningstar

CureVac N.V. Schedules EGM for BioNTech SE Exchange Offer and Post-Offer Reorganization

CVAC

M&A

Takeover Bid

Board Change

CureVac N.V. will hold an Extraordinary General Meeting (EGM) on November 25, 2025, to vote on the post-offer reorganization related to BioNTech SE's exchange offer for its ordinary shares.
BioNTech SE's exchange offer, which began on October 21, 2025, is set to expire on December 3, 2025, at 9:00 a.m. New York City time.
The proposed post-offer reorganization includes a Legal Downstream Merger of CureVac N.V. into CureVac Merger B.V. ("New Topco"), followed by the sale of CureVac SE shares to BioNTech SE and the cancellation of New Topco A shares.
The reorganization is conditional on BioNTech SE acquiring at least 80% (or 75% if amended) of CureVac's outstanding share capital.
Shareholders who do not tender their shares in the offer may incur Dutch dividend withholding tax on the cancellation consideration, potentially resulting in a lower after-tax return.